Inflammatory disease Archives

News and Trends 12 Oct 2015

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory diseases such as Rheumatoid Arthritis. Using the mAb humanisation platform licensed from Abzena (a life Sciences group from Cambridge, UK), Adheron Therapeutics will now be acquired by Swiss giant Roche for €509M. Abzena, based in […]

October 12, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

As we reported last Monday, the AbbVie–Galapagos relationship has proven to be rather rocky as of late, with dramatic action down the NASDAQ Stock exchange. After AbbVie pulled out of the Galapagos Rheumatoid Arthritis pipeline, recent success with their joint-research in Cystic Fibrosis (CF) may kick-start the healing process. Their transport protein potentiator therapy for […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

Biotech of the week: Enterome, the Leading French Microbiome Start-up

This week we’ve left the sunny Portuguese coast behind us and arrived in the ‘City of Lights’, Paris. The capital city of France is famous for the Eiffel Tower, fashion and cuisine but what you may not know it is home to Enterome Bioscience, a pioneer in personalized therapies that focus on microbiome related diseases. […]

October 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Oct 2015

Biotech of the week: Cell2b, the Promising Portuguese Cell Therapy Biotech

As it’s a new month, we thought we would try something a little different on Labiotech.eu. Every week we are going to showcase a company of our choice found on our map. The goal is to keep everybody up to date on all the various biotech and pharma companies that are found throughout Europe. This week […]

October 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 4 Sep 2015

Gut bacteria growth time can cause disease?

A method of profiling bacterial growth time in the gut’s microbiome has been shown to be a rudimentary diagnostic tool for IBS and diabetes type II. A research team came together from the labs of Dr Elinav and Professor Segal to investigate at the Weizmann Institute of Science, Israel. The millions of bacteria living within our […]

September 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Paris based Sanofi has pulled out of a €176M deal with Californian clinical stage biotech Ardelyx. A licensing deal for a program of pre-clinical candidates treating renal diseases and IBS-C, similar to Tenapanor, was revoked. In February 2015, Fresno County’s Ardelyx announced its pharma-baby, Tenapanor, had passed its stage IIB clinical trials in successfully reducing serum levels of phosphate. […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 6 Aug 2015

Now it’s Clear, AbbVie Has to Buy Galapagos’ Drug

Galapagos just disclosed new good results of its Phase 2B study in rheumatoid arthritis. The drug could be a lifesaver for AbbVie, which is facing patent lost of its most profitable drug Humira. Mechelen, Belgium-based Galapagos NV announced today that at week 24, patients treated with the selective JAK1 inhibitor filgotinib showed further improvement in signs […]

August 6, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 Jul 2015

Ferring bets on bacteriophages to treat inflammatory bowel disease

Bacteriophages have been instinctively killing bacteria for millions of years. These natural bacteria predators represent a potential alternative to antibiotics and Ferring Pharmaceuticals wants to use them against inflammatory bowel disease. The Swiss pharma joined forces with phages specialist Intralytix to manufacture these viruses for clinical purposes. Bacteriophages can be very selective when it comes […]

July 15, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Jul 2015

Green light for one of the largest clinical trials in Immunotherapy

In a period, where uncountable big pharmas and biotechs are struggling to get the largest piece of the immunotherapy cake, an unexpected player has arrived. TxCell, a French biotech, received an option to extend its current phase IIb study from EU to US, a stage that lots of immunotherapy experts would like to reach. TxCell was founded fourteen years […]

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 May 2015

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown, from 70 to more than 400 employees and from €70M to around €1.2Bn in market capitalization. Galapagos recently reported positive results with its JAK1 inhibitor in nearly 900 rheumatoid arthritis patients worldwide, triggering the interest […]

May 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 14 Mar 2015

Samsung Bioepis Submits a Biosimilar Candidate, to the European Medicines Agency

Samsung Bioepis announced their submission to the to the European Medicines Agency (EMA) for SB2, its Remicade (Infliximab) biosimilar candidate. This is the second biosimilar candidate Marketing Authorization Application (MAA) that Samsung Bioepis has submitted to the EMA. The MAA is based on results from an extensive head-to-head preclinical data package comparing SB2 to the originator, a […]

March 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Feb 2015

Celltrion launches world’s first biosimilar monoclonal antibody in 12 new European markets

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. The treatment to the treatment of autoimmune diseases is now available in 31 countries. Remsima, developed by the South Korean company Celltrion, is the world’s first biosimilar monoclonal […]

February 26, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us